Articles tagged "Kidney transplantation"

2018 American Transplant Congress
How Safe is Immunosuppression Maintenance 1 Year after Renal Allograft Failure?
A. Mena-Gutierrez, K. Alquadan, A. Santos, K. Womer, M. Casey.
University of Florida, Gainesville.
In 2013, our center opened a specialty clinic to maintain immunosuppression (IS) after renal graft failure in an attempt to minimize further sensitization in retransplant…
2018 American Transplant Congress
A Novel, Dose-Adjusted Tacrolimus Intrapatient Variability Model Identifies High-Risk Kidney Transplant Recipients Better Than Existing Methodologies
J. Kim, S. Wilson, Y. Song, J. Schwartz.
Astellas Pharma Global Development, Inc., Northbrook.
Intrapatient variability (IPV) of tacrolimus trough concentration (TTC) is a risk factor for inferior transplant outcomes. However, assessing IPV is problematic, relying on fixed dose…
2018 American Transplant Congress
Outcomes of Donor and Recipient Obesity in Kidney Transplantation
J. Buggs,¹ R. Mehta,² M. Adesunkanmi,² J. Boone,² E. Rogers,³ A. Kumar,⁴ V. Bowers.¹
¹Transplant Surgery, Tampa General Medical Group, Tampa General Hospital, Tampa, FL; ²Pre-Med Undergraduate, University of South Florida, Tampa, FL; ³Transplant Research, Tampa General Hospital, Tampa, FL; ⁴Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL.
Introduction: Obesity (BMI >30) is a world health epidemic projected to increase the incidence of diabetes, the leading cause of kidney failure. The shortage of…
2018 American Transplant Congress
The Role of Pre-Emptive Antibiotic Therapy in Kidney Recipients of Donors with Urine-Only Positive Cultures
P. Cabrera,¹ A. Centeno,¹ J. Revollo,¹ J. Camargo.²
¹Department of Pharmacy, Jackson Memorial Hospital, Miami, FL; ²Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.
Background: Donor derived infections (DDIs) can lead to significant morbidity and mortality in solid organ transplant patients. In recent years, the disparity between the need…
2018 American Transplant Congress
End Stage Kidney Disease Risk Profile in Living Kidney Donors for Pediatric versus Adult Kidney Transplant Recipients in Australia and New Zealand
D. Lee,^1,2 J. Whitlam,² N. Cook,² A. Walker,³ F. Ierino,⁴ M. Roberts,¹ J. Kausman.³
¹Department of Renal Medicine, Eastern Health, Melbourne, VIC, Australia; ²Department of Nephrology, Austin Health, Melbourne, VIC, Australia; ³Department of Nephrology, Royal Children's Hospital, Melbourne, VIC, Australia; ⁴Department of Nephrology, St Vincent's Hospital, Melbourne, VIC, Australia.
Background: Living kidney donors (LKD) for pediatric kidney transplant recipients (KTR) have a high motivation to donate due to the clear benefits to the KTR…
2018 American Transplant Congress
New SLK Allocation Policy May Impact Transplant Outcomes in Women
G. Cullaro,¹ R. Hirose,² J. Lai.¹
¹Medicine, University of California, San Francisco, San Francisco, CA; ²Transplant Surgery, University of California, San Francisco, San Francisco, CA.
Background: Previous SLK allocation was based on serum creatinine(Cr), a metric that disadvantaged women(W) relative to men(M). A SLK policy change utilizes eGFR, which accounts…
2018 American Transplant Congress
Hypothermic Machine Perfusion Protects Rabbit Kidney Graft through Down Regulation SPP1-MMP7 Signaling Axis
Q. Hu,¹ Z. Zhong,¹ S. Xue,¹ W. Liang,¹ J. Lan,¹ J. Liang,¹ Y. Xiong,¹ Y. Wang,¹ Q. Ye.^1,2
¹Zhongnan Hospital of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, China; ²The 3rd Xiangya Hospital of Central Sourth University, Changsha, China.
Background: Multicenter studies have indicated that hypothermic machine perfusion(HMP) can be used to prolong cold ischemia time with high-quality preservation and allow utilization of kidney…
2018 American Transplant Congress
The Role of Donor-Derived Cell-Free DNA in Identification of Injury in Kidney Allografts with Antibody-Mediated Rejection and De Novo DSA
H. Zhang,¹ L. Liu,¹ C. Zheng,² X. Li,¹ Q. Fu,¹ J. Li,¹ Q. Su,¹ H. Huang,¹ M. Ye,² C. Wang.¹
¹Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; ²BGI-Guangzhou Medical Laboratory, BGI-Shenzhen, Guangzhou, China.
Objectives: To evaluate the capacity of donor-derived cell-free DNA (dd-cfDNA) in the identification of injury in kidney allografts with antibody-mediated rejection and de novo DSA.Methods:…
2018 American Transplant Congress
Allograft Function after 12 Months with Everolimus Plus Either Tacrolimus or Cyclosporine Compared to a Standard Regimen of Tacrolimus with MPA in De Novo Renal Transplant Recipients: The ATHENA Study
B. Nashan,¹ C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ O. Witzke,¹ C. Hugo,¹ N. Kamar,² P. Merville,² A. Hauser,¹ P. Schenker,¹ M. Junge,³ F. Thaiss.¹
¹Athena Study Group, Germany; ²Athena Study Group, France; ³Novartis, Pharma, Germany.
The ATHENA study was designed to compare efficacy, safety and outcomes on renal function [GFR] of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A…
2018 American Transplant Congress
Recurrent FSGS Post-Transplantation: Prevalence and Risk Factors
R. Aguiar,¹ A. Gasparini,² P. Chowdhury,¹ D. Game,¹ D. Moutzouris.¹
¹Department of Nephrology and Transplantation, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; ²Department of Health Sciences, University of Leicester, Leicester, United Kingdom.
Introduction: Primary FSGS can recur in the renal allograft and is associated with poor outcomes. The aim of this study was to assess the prevalence…